Acute graft-vs-host disease (aGVHD) after orthotopic liver transplantation (OLT) is rare, with a reported incidence of 0.1% to 2%. Mortality remains high when marrow involvement causes pancytopenia and infection.1–5 Post-solid organ transplant aGVHD usually develops within 2 to 12 weeks after transplantation and is mediated by donor-derived T cells that recognize recipient tissues as foreign.6–8 In contrast to chronic graft-vs-host disease (GVHD), which is defined by characteristic clinical manifestations rather than timing alone, acute disease is distinguished by its clinicopathologic pattern.9Passenger lymphocyte syndrome (PLS) is a donor B-cell-mediated complication in which antibodies against recipient red-cell antigens cause hemolysis. It occurs most often after minor ABO blood group system (ABO) mismatch, although Rh and other red-cell antigen mismatches can also cause hemolysis.10–13 In 1 liver transplant series, PLS occurred in 10 of 56 minor ABO-incompatible recipients. All cases were self-limited, and most patients received donor-compatible red-cell transfusions.12Against this background, we report sequential PLS followed by skin-predominant aGVHD after OLT. This case illustrates how 2 donor lymphocyte-mediated complications can occur in sequence and how clinical pattern, biopsy findings, and chimerism testing should be integrated when assessing prognosis.
CASE REPORT
A 63-year-old woman with end-stage liver disease from primary biliary cholangitis and autoimmune hepatitis underwent deceased donor OLT with a donation-after-circulatory-death graft from an O-positive donor approximately 20 years younger than the A-positive recipient. The patient received methylprednisolone 500 mg intravenously for induction. Maintenance immunosuppression included mycophenolate mofetil 1 g twice daily, tacrolimus 2 mg twice daily, and a corticosteroid taper.On postoperative day (POD) 1, hemoglobin fell to 5.6 g/dL without documented bleeding. Platelets reached their lowest value of 13 K/uL during the first postoperative week. Lactate dehydrogenase peaked at 401 IU/L, haptoglobin was undetectable, and direct antiglobulin testing (DAT) was immunoglobulin G-positive and C3-negative. Recipient pretransplant anti-A titer was less than 2, which suggested minimal baseline antibody. Donor isohemagglutinin titers were not available, and eluate testing was not performed. In this setting, PLS was favored over surgical bleeding, delayed hemolytic transfusion reaction, or drug-induced hemolysis. The peripheral smear showed spherocytes without schistocytes, which made thrombotic microangiopathy less likely.(A) Pretreatment photograph at rash evaluation on postoperative day 59 showing confluent erythema with fine scale and papules coalescing into plaques on the lower extremities. (B) Follow-up photograph approximately 3 weeks after corticosteroid initiation showing near-complete improvement.Tacrolimus was discontinued during the first postoperative week after confusion and a fall raised concern for neurotoxicity. Cyclosporine 100 mg twice daily was started, with a target trough of 150–200 ng/mL. She received 9 units of group O packed red cells and 3 units of platelets over 2 months. Mycophenolate mofetil was changed to mycophenolic acid 720 mg twice daily on POD 53 because of gastrointestinal symptoms. She was not receiving corticosteroids immediately before rash onset.On POD 55, she developed an intensely pruritic rash that began in the inframammary and gluteal folds and then spread to the hands, feet, legs, and back (Figures 1–3). Posterior pharyngeal erythema with white spots was also noted. She reported burning pain, sore throat, nausea, poor appetite, and low-grade fevers. She did not have diarrhea, abdominal pain, respiratory symptoms, or bleeding.(A) Pretreatment photograph at rash evaluation on postoperative day 59 showing a hyperkeratotic scaly plaque with surrounding erythema on the elbow. (B) Follow-up photograph 5 days after corticosteroid initiation showing marked improvement.Examination showed confluent thigh erythema with fine scale, palmoplantar hyperkeratosis, dorsal hand and foot papules that coalesced into plaques, and lateral nailfold purpura (Figures 2 and 3). Testing for parvovirus B19, respiratory viruses, Epstein–Barr virus, cytomegalovirus, group A streptococcus, and bloodstream infection was negative except for 1 blood culture that grew Staphylococcus epidermidis and was considered a contaminant. Oral candidiasis, mucositis, and oral GVHD were considered. The oral lesions did not have removable plaques but got better with steroid initiation, and hence, no oral biopsy was performed.Right thigh punch biopsy on POD 60 showed lichenoid interface dermatitis with vacuolar basement-membrane alteration and frequent dyskeratotic keratinocytes extending into follicular epithelium. These findings were concerning for aGVHD. Peripheral blood short tandem repeat chimerism on POD 59 showed 1% donor-derived DNA in CD3+ T cells and less than 1% in CD33+ myeloid cells. Drug eruption, viral exanthem, fungal infection, and contact dermatitis were considered less likely because of the biopsy pattern, negative infectious workup, limited response to topical and antifungal therapy, and supportive donor T-cell chimerism. Bone marrow biopsy was not performed because there was no progressive pancytopenia, aplastic pattern, or other clinical evidence of marrow involvement. No endoscopy was performed during the hospitalization for the rash because symptoms did not suggest gastrointestinal GVHD.Methylprednisolone 85 mg twice daily, approximately 1 mg/kg twice daily based on weight 87.5 kg, was started on POD 61. The rash improved markedly within 24 h (Figures 1–3). Cyclosporine was temporarily held during hospitalization and restarted before discharge, although the rationale for the hold was not clearly documented. She was discharged on POD 69 on prednisone 100 mg twice daily with taper, cyclosporine 100 mg twice daily, valganciclovir 900 mg daily, and trimethoprim-sulfamethoxazole 400-80 mg 3 times weekly. Mycophenolic acid remained held. Hemoglobin remained above 10 g/dL by POD 73, and follow-up through 8 months showed no recurrent rash or GVHD. The clinical timeline and significant laboratory findings are summarized in Figure 4 and Table 1, respectively.(A) Pretreatment photograph at rash evaluation on postoperative day 59 showing prominent palmoplantar hyperkeratosis with bilateral scaling. (B) Follow-up photograph approximately 3 weeks after corticosteroid initiation showing significant improvement in hyperkeratosis and scaling.
DISCUSSION
PLS and aGVHD share an origin in donor lymphocytes, but their effector cells and clinical targets are different. PLS is donor B-cell-mediated hemolysis against recipient red-cell antigens and usually appears within the first weeks after minor ABO-mismatched transplantation.10–13 aGVHD reflects donor T-cell recognition of host tissues, and it most often affects the skin, gastrointestinal tract, liver, and bone marrow.6–8 In this patient, the early hemolytic episode and later cutaneous eruption represented 2 distinct immune complications rather than a single evolving process.The initial presentation was most consistent with PLS because abrupt, otherwise unexplained anemia occurred after minor ABO-mismatched OLT and was accompanied by low haptoglobin, elevated lactate dehydrogenase, and a positive DAT. Concurrent thrombocytopenia made the presentation more complex, but the absence of bleeding and schistocytes, together with donor-compatible transfusion requirement, supported PLS over surgical hemorrhage or thrombotic microangiopathy. The later rash met a separate diagnostic pattern for aGVHD because clinical findings, biopsy, and donor T-cell chimerism aligned with cutaneous disease.Clinical timeline summarizing orthotopic liver transplantation, onset of passenger lymphocyte syndrome, calcineurin-inhibitor changes, rash onset, diagnostic testing, corticosteroid therapy, discharge, and follow-up by postoperative timing.Mortality in post-OLT aGVHD exceeds 70% in many series and is driven mainly by marrow aplasia and infection rather than rash alone.1–5 This patient's favorable course likely reflected several factors acting together. Dermatology was involved early, skin biopsy was obtained promptly, corticosteroids were started quickly, and there was no clinical evidence of gastrointestinal or marrow involvement. A contrasting fatal case with grade IV aGVHD involving skin, gut, and liver illustrates why the extent of organ involvement remains central to prognosis.14The chimerism result also required to be viewed in the right context. Low-level donor CD3+ cells can occur after OLT without clinical aGVHD. Domiati-Saad et al15 reported an upper 99% confidence limit of approximately 3% donor CD3+ cells at week 8, whereas markedly higher or persistent levels were more suggestive of clinical aGVHD. For that reason, this patient's 1% donor-derived CD3+ signal was not diagnostic by itself but was supportive when interpreted with the compatible rash, biopsy findings, and response to therapy.Key laboratory values across three clinical phases with postoperative day timingaGVHD, acute graft-vs-host disease; ALT, alanine aminotransferase; ANC: absolute neutrophil count; AST, aspartate aminotransferase; DNA, deoxyribonucleic acid; IgG, immunoglobulin G; LDH, lactate dehydrogenase; N/A, not applicable; OLT, orthotopic liver transplantation; POD, postoperative day; PLS, passenger lymphocyte syndrome; WBC, white blood cell.Tacrolimus was replaced by cyclosporine for suspected neurotoxicity rather than directed PLS therapy. Although the cyclosporine trough near rash onset was slightly below goal, this single case cannot establish that the switch contributed to donor T-cell expansion. The association can be best viewed as temporal and hypothesis-generating.Clinicians should consider PLS when hemolysis develops after minor ABO- or red-cell antigen-mismatched transplant, and they should also consider aGVHD when fever, rash, diarrhea, liver dysfunction, or cytopenias arise after OLT. Neither skin histology nor low-level chimerism should be interpreted in isolation. Early biopsy, integrated clinical assessment, and prompt treatment remain essential when these rare complications are suspected.16
DISCLOSURES
Author contributions: All authors contributed to the study's conception and design. Patient consent was obtained by U. Sharma. Clinical care was provided by MK Rude, MK Gangwani, M. Deneke, and Y. Shah. The first draft of the manuscript was written by U. Sharma and Y. Shah. MK Rude, MK Gangwani, and M. Deneke contributed to editing and final review. All authors read and approved the final manuscript. U. Sharma is the article guarantor.Informed consent was obtained for this case report.Financial disclosure: None to report.
YS
Dr. Yash Shah
Gastroenterology · General GastroenterologyUniversity of Arkansas for Medical Sciencesyashs